[go: up one dir, main page]

WO2012158591A1 - Produits et méthodes anti-blépharite - Google Patents

Produits et méthodes anti-blépharite Download PDF

Info

Publication number
WO2012158591A1
WO2012158591A1 PCT/US2012/037724 US2012037724W WO2012158591A1 WO 2012158591 A1 WO2012158591 A1 WO 2012158591A1 US 2012037724 W US2012037724 W US 2012037724W WO 2012158591 A1 WO2012158591 A1 WO 2012158591A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
phase
weight
blepharitis
shale oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/037724
Other languages
English (en)
Inventor
Shetal A. SHAH
Monica DWECK
Ronald J. Bohm
Amit R. Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RESOURCES OF NATURE Inc
Research Foundation of the State University of New York
Original Assignee
RESOURCES OF NATURE Inc
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RESOURCES OF NATURE Inc, Research Foundation of the State University of New York filed Critical RESOURCES OF NATURE Inc
Publication of WO2012158591A1 publication Critical patent/WO2012158591A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the disclosure relates generally to the field of products that can prevent or treat blepharitis. More specifically, the present disclosure is directed to preventing or treating blepharitis through application of various cosmetics.
  • Blepharitis is one of the most common ocular disorders, affecting millions of Americans. Blepharitis is a continuum of inflammatory disease processes of the eyelid and can be divided anatomically into anterior and posterior blepharitis. Anterior blepharitis is inflammation around the eyelashes and follicles, while posterior type involves the meibomian glands. The
  • pathophysiology of blepharitis involves bacterial colonization of the eyelids. This bacterial colonization results in immune mediated inflammatory damage to the surrounding tissues.
  • formulations of cosmetics that can be used to treat or prevent blepharitis. Further, what is desired are formulations that have anti-bacterial and antiinflammatory effects that can be used as cosmetics.
  • Embodiments of the present application provide products and methods that address the above and other issues.
  • the present disclosure is directed to a cosmetic composition and methods for treating or preventing blepharitis.
  • the process is directed towards a cosmetic composition comprising verbascoside and a shale oil.
  • the present disclosure is also directed to a method for preventing blepharitis comprising administering a therapeutic amount of verbascoside and a shale oil.
  • the present disclosure is also directed to a method for treating blepharitis comprising administering a therapeutic amount of verbascoside and a shale oil.
  • compositions of the present disclosure provide improvements over traditional cosmetics that cause or exacerbate blepharitis symptoms.
  • the improvements are, inter alia, treatment or prevention of blepharitis symptoms and blepharitis through application of the described cosmetic compositions.
  • Various cosmetic compositions are disclosed herein.
  • Each cosmetic composition includes both 2-(3',4'-dihydroxyphenyl)ethyl-0-a-l-rhamnopyranosyl-(l ⁇ 3)- -d-(4-0- caffeoyl)-glucopyranoside (Verbascoside), also known as kusaginin or acetoside, and a shale oil, among other components.
  • These other components can include one or more cosmetically suitable excipients such as glycerine and xantham gum.
  • These other components comprise the balance of the total composition as further illustrated among the several examples below, with their individual concentrations depending on the kind of cosmetic composition being produced. Individual concentrations of the suitable excipients are listed in the examples, but these individual concentrations may be modified in either direction, higher or lower percentage, as needed.
  • the shale oil can be any shale oil suitable for topical use including light-colored pale sulfonated shale oil (ICHTHYOL® pale) and dark sulfonated shale oil (ICHTHYOL®).
  • the shale oil can be present in concentrations ranging from 0.0001% by weight to about 10% by weight of the total composition.
  • the shale oil is useful as an anti-inflammatory, anti -bacterial and antimycotic when applied topically and is also water soluble.
  • the other components can include a metal ion carrier that can contain any suitable metal ion that is capable of offering and anti-inflammatory or anti-bacterial effect.
  • the inorganic metal ion carrier can be an inorganic silver ion carrier.
  • the inorganic silver ion carrier can be Ionpure® WP A glass powder, among others.
  • Ionpure® is an inorganic, soluble glass containing anti-bacterial metal ions.
  • the Ionpure® glass particles are non- volatile, heat resistant and in the presence of water or moisture, will release the metal ions gradually.
  • Metal ions, such as silver ions, are taken into microbes where they react, bond and inhibit the microbe's enzyme activity and can reduce multiplication of the microbes. These microbes can include blepharitis causing bacteria.
  • the other components can also include glycerophosphoinositol (GPI) lysine.
  • GPI Lysine such as Distinctive® GPI Lysine offered by Resources of Nature, Inc. South Plainfield, New Jersey, is useful as an anti-inflammatory and anti-itch substance.
  • GPI lysine is stable over a broad range of temperatures and pH's and can be present in concentrations ranging from
  • Verbascoside is an effective cellular protectant that can be applied topically.
  • Verbascoside can be isolated or extracted from various raw materials.
  • verbascoside can be gathered from the leaves of the buddleja cordata tree. The leaves can be dried, ground and extracted with hexane and methanol. The methanolic portion is evaporated to obtain a crude syrup that is further treated to produce a verbascoside amorphous powder.
  • Verbascoside is a phenylpropanoid glycoside (PPG) that is a water soluble derivative of phenylpropanoid (PP).
  • PPG phenylpropanoid glycoside
  • PP phenylpropanoid
  • Verbascoside has a strong anti-inflammatory and anti-bacterial activity.
  • Distinctive® Phytostem Lilac is one example of a material containing verbascoside, but any other suitable verbascoside containing material could also be used.
  • Distinctive® Phytostem Lilac is a cell culture extract titrated in verbascoside.
  • the verbascoside and shale oil can be encapsulated, the shale oil and the GPI lysine can also be encapsulated.
  • the encapsulated materials can be immediate, sustained or a mixture of immediate and sustained release encapsulations.
  • the materials can be encapsulated in any suitable manner, such as the encapsulation methods described in European Patent EP0966268 and those described in "Drug Delivery: Principles and Applications" by Wang, et al. (John Wiley & Sons, Inc. 2005), both of which are incorporated by reference.
  • the verbascoside and the inorganic metal ion carrier can be differing concentrations based on the desired result.
  • the verbascoside can be about 0.0001% by weight to about 10% by weight of the composition and the inorganic metal ion carrier can be about 0.0001% by weight to about 10% by weight.
  • the cosmetic composition can be one of many cosmetic compositions, which can include lotions, creams, eye pencils, eye shadows, hydroalcoholic liquid or spray, primer, serum, mascara, eye liner and a single phase liquid or spray. These cosmetic compositions can be applied topically on any exposed skin surface that could be affected by blepharitis including, but not limited to, eye lids and the areas surrounding each of the eyes. These cosmetic compositions can be formed using various manufacturing techniques, some of which are described throughout the examples below. Blepharitis can have many different causes, including but not limited to Staphococyl, Seborrheaic, Allergies, Lice, cosmetic products and others from other sources other than cosmetic products.
  • the disclosure also includes a method for preventing or treating blepharitis that includes administering a therapeutic amount of verbascoside and shale oil.
  • the administration of the verbascoside and shale oil is useful in both preventing the presence of blepharitis and blepharitis symptoms, it is also useful in treating the severity of the blepharitis and blepharitis symptoms such as the reduction of sebum production, reduction of bacterial growth and the unclogging of skin's pores.
  • the combination of verbascoside and shale oil provides improved blepharitis prevention and treatment as compared to the administration of verbascoside alone or shale oil alone.
  • the combination can be synergistic, e.g., where the joint action of two or more components is such that the combined effect is greater than the sum of their individual effects.
  • ICHTHYOL® pale is included.
  • lonpure® WPA glass powder can also be used, instead of or in combination with ICHTHYOL® pale, in similar percentages by weight.
  • composition is an oil in water lotion:
  • the oil in water lotion is formed by first preparing phase A by adding Butylene glycol, glycerine and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D and E ingredients are then added.
  • composition is an oil in water cream:
  • the oil in water cream is formed by first preparing phase A by adding Butylene glycol, glycerine and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase D, E and F ingredients are then added.
  • composition is water in oil lotion:
  • Salicylic Acid (as 0.1% to applicable) 20%
  • the water in oil lotion is formed by first preparing phase A by adding Butylene glycol, glycerine, sodium chloride, sodium borate and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
  • composition is water in oil cream:
  • the water in oil cream is formed by first preparing phase A by adding Butylene glycol, glycerine, sodium chloride, sodium borate and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
  • composition is for an eye pencil "A":
  • the eye pencil "A” is formed by mixing all components of Phase A together until uniform and forming the mixed components into a suitable shape for application to a user's eye.
  • composition is for an eye pencil "B":
  • the eye pencil "B" is formed by combining all components of Phase A and heating the mixture to 95 °C. After heating, the mixture is mixed until uniform and cooled to room temperature. The mixture is then formed into a suitable shape for application to a user's eye.
  • composition is for an eye shadow:
  • composition is for a silicon in water lotion:
  • the silicon in water lotion is formed by first preparing phase A by adding Butylene glycol, glycerin and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
  • composition is for a water in silicone lotion:
  • the water in silicone lotion is formed by first preparing phase A by adding Butylene glycol, glycerin, sodium chloride and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
  • composition is for a hydroalcoholic liquid or spray:
  • the hydroalcoholic liquid or spray is formed by first preparing phase A by combining all Phase A components. Next, the Phase B, C, D and E components are mixed together and combined with the Phase A components. [0043] In the following example, the composition is for a cosmetic primer:
  • Cosmetic primer is formed by first preparing phase A by combining all Phase A components. Next, the Phase E, F and G components are mixed together and combined with the Phase A components. owing example, the composition is for a cosmetic serum:
  • the cosmetic serum is formed by first preparing phase A by adding Butylene glycol, glycerin, glyceryl acrylate/acrylic acid copolymer and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E, F and G components are then added.
  • composition is for a mascara:
  • Camauba Wax (Copernicia Cerifera (Carnauba) Wax) 5.00
  • Salicylic Acid 0.1% to 20%
  • Phase C Retinol or Retinol derivatives 0.01% to 0.25%
  • Distinctive® Phytostem Lilac 50 (Maltodextrin (and) Syringa Vulgaris
  • Colorants qs [0048] All percentages above are based on weight.
  • the cosmetic serum is formed by first preparing phase A by adding all the components, the combination is then heated to 85 °C. Next, the Phase B ingredients are mixed together and heated to 85-90 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E, F and G components are then added.
  • composition is for a waterproof mascara:
  • Waterproof mascara is formed by first preparing phase A by combining all Phase A components and heating them to 95 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye. [0051] In the following example, the composition is for an eyeliner containing iron oxide
  • Eyeliner containing iron oxide is formed by first preparing phase A by combining all Phase A components and heating them to 85 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye.
  • composition is for an eyeliner:
  • Eyeliner is formed by first preparing phase A by combining all Phase A components and heating them to 85 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye.
  • Example 17
  • composition is for an anhydrous eyeliner:
  • Anhydrous eyeliner is formed by first preparing phase A by combining all Phase A components and heating them to 95 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye.
  • composition is for a mascara containing iron oxide:
  • the mascara containing iron oxide is formed by first preparing phase A by adding all the components, the combination is then heated to 85 °C. Next, the Phase B ingredients are mixed together and heated to 85-90 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E, F and G components are then added.
  • composition is for a single phase cosmetic liquid or spray:
  • a single phase cosmetic liquid or spray is formed by first preparing phase A by combining all Phase A components. The components are mixed until uniform, and added to the Phase B, C, D and E components.
  • composition is for a wet wipe cloth and liquid:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition cosmétique et des méthodes de traitement ou de prévention de la blépharite. L'invention concerne, donc, une composition cosmétique contenant du verbascoside et une huile de schiste. La présente invention concerne également une méthode de prévention de la blépharite impliquant l'administration d'une quantité thérapeutique de verbascoside et d'une huile de schiste. La présente invention concerne, en outre, une méthode de traitement de la blépharite impliquant l'administration d'une quantité thérapeutique de verbascoside et d'une huile de schiste.
PCT/US2012/037724 2011-05-18 2012-05-14 Produits et méthodes anti-blépharite Ceased WO2012158591A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161487430P 2011-05-18 2011-05-18
US61/487,430 2011-05-18

Publications (1)

Publication Number Publication Date
WO2012158591A1 true WO2012158591A1 (fr) 2012-11-22

Family

ID=47177293

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/037724 Ceased WO2012158591A1 (fr) 2011-05-18 2012-05-14 Produits et méthodes anti-blépharite

Country Status (1)

Country Link
WO (1) WO2012158591A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20130763A1 (it) * 2013-05-09 2014-11-10 Altergon Sa Preparazioni topiche monodose e multidose per il trattamento di stati infiammatori delle mucose e della cute
WO2016000663A1 (fr) * 2014-07-03 2016-01-07 杏辉天力（杭州）药业有限公司 Applications de l'extrait de cistanche tubulosa dans la préparation d'un médicament ou produit de protection les cellules de l'œil
US9642887B1 (en) * 2015-12-28 2017-05-09 Shetal Amit Shah Anti-blepharitis compositions and their use
IT202100028220A1 (it) * 2021-11-05 2023-05-05 Novax Pharma Sam Ophthalmic composition comprising a lubricant agent and verbascoside, and use of said composition for the preventive or curative treatment of a corneal epithelial defect and/or a conjunctival defect in a subject

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102289A1 (en) * 2000-11-30 2002-08-01 Anja Drucks Cosmetic or dermatological impregnated wipes
US20050031547A1 (en) * 2003-08-04 2005-02-10 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7625883B1 (en) * 2000-11-07 2009-12-01 I.R.B. Istituto di Ricerche Biotechnologiche S.R.L. Glycerophosphoinositol derivatives as modulators of cytosolic A2 phospholipase
US20100086502A1 (en) * 2008-10-08 2010-04-08 L'oreal Cosmetic/sunscreen compositions containing dibenzoylmethane compounds and dithiolane compound photostabilizers therefor
US7718199B2 (en) * 2005-06-20 2010-05-18 I.R.B. Istituto Di Ricerche Biotecnologiche S.R.L. Extracts obtained from cell line cultures from plants belonging to the Oleaceae family (e.g. Syringa vulgaris), their preparation and use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625883B1 (en) * 2000-11-07 2009-12-01 I.R.B. Istituto di Ricerche Biotechnologiche S.R.L. Glycerophosphoinositol derivatives as modulators of cytosolic A2 phospholipase
US20020102289A1 (en) * 2000-11-30 2002-08-01 Anja Drucks Cosmetic or dermatological impregnated wipes
US20050031547A1 (en) * 2003-08-04 2005-02-10 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7718199B2 (en) * 2005-06-20 2010-05-18 I.R.B. Istituto Di Ricerche Biotecnologiche S.R.L. Extracts obtained from cell line cultures from plants belonging to the Oleaceae family (e.g. Syringa vulgaris), their preparation and use
US20100086502A1 (en) * 2008-10-08 2010-04-08 L'oreal Cosmetic/sunscreen compositions containing dibenzoylmethane compounds and dithiolane compound photostabilizers therefor

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20130763A1 (it) * 2013-05-09 2014-11-10 Altergon Sa Preparazioni topiche monodose e multidose per il trattamento di stati infiammatori delle mucose e della cute
WO2014180565A1 (fr) * 2013-05-09 2014-11-13 Altergon S.A. Préparations topiques comprenant de l'acide hyaluronique, du verbascoside et du glycérophosphoinositol
US20160113960A1 (en) * 2013-05-09 2016-04-28 Altergon S.A. Topical preparations comprising hyaluronic acid, verbascoside and glycerophosphoinositol
WO2016000663A1 (fr) * 2014-07-03 2016-01-07 杏辉天力（杭州）药业有限公司 Applications de l'extrait de cistanche tubulosa dans la préparation d'un médicament ou produit de protection les cellules de l'œil
US10967029B2 (en) 2014-07-03 2021-04-06 Sinphar Pharmaceutical Co., Ltd. Method of using Cistanche tubulosa extract to prevent, slow down, or treat an eye disease caused by oxidative stress
US9642887B1 (en) * 2015-12-28 2017-05-09 Shetal Amit Shah Anti-blepharitis compositions and their use
EP3187186A1 (fr) * 2015-12-28 2017-07-05 Shetal Amit Shah Compositions anti-blépharite et leurs utilisations
IT202100028220A1 (it) * 2021-11-05 2023-05-05 Novax Pharma Sam Ophthalmic composition comprising a lubricant agent and verbascoside, and use of said composition for the preventive or curative treatment of a corneal epithelial defect and/or a conjunctival defect in a subject
WO2023079520A1 (fr) 2021-11-05 2023-05-11 Novax Pharma Sam Composition ophtalmique comprenant un agent lubrifiant et du verbascoside, et utilisation de cette composition pour le traitement préventif ou curatif d'une lésion épithéliale de la cornée et/ou d'une lésion conjonctivale chez un sujet

Similar Documents

Publication Publication Date Title
US20060165644A1 (en) Cosmetics
KR101425031B1 (ko) 유자씨 및 망고씨 혼합오일을 함유하는 피부 자극완화 및 피부보습용 화장료 조성물
CN115006285A (zh) 冰沙状卸妆组合物及其制备方法
US20140106009A1 (en) Methods and compositions for maintaining and improving the health of skin
JP3556595B2 (ja) レチノール及び表皮成長因子を含有する皮膚保護用化粧料組成物
US9642887B1 (en) Anti-blepharitis compositions and their use
EP3761952B1 (fr) Compositions topiques de soins de la peau
WO2014094377A1 (fr) Composition de venin d'abeille ayant des effets de protection et d'embellissement des lèvres
WO2012158591A1 (fr) Produits et méthodes anti-blépharite
KR20200073970A (ko) 수딩 크림 및 이의 제조 방법
EP2983684B1 (fr) Huile essentielle et aloès pour le traitement et la prophylaxie d'inflammations provoquées par demodex, notamment la blépharite marginale, composition pharmaceutique contenant une huile essentielle et/ou de l'aloès et utilisation de l'huile essentielle et de l'aloès et de leurs compositions pour la production d'une préparation utilisée dans le traitement et la prophylaxie des inflammations mentionnées
CN103494737B (zh) 一种以姜花作为抗衰老护肤因子的化妆品制剂及制备方法
KR102214985B1 (ko) 식물추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 상태 개선용 조성물
KR101418366B1 (ko) 봉독 및 프로폴리스를 함유하는 여드름 예방 또는 치료용 조성물
KR102736636B1 (ko) 맥주효모 추출물을 포함하는 두피개선용 조성물
CN103006530A (zh) 一种具有防晒功效的蜂毒组合物
KR20210018388A (ko) 식물추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 상태 개선용 조성물
CN107875079B (zh) 一种去脂肪粒精华及其制备方法
KR102801893B1 (ko) 나노화된 벌화분 추출물을 유효성분으로 포함하는 여드름 치료용 조성물
WO2016033899A1 (fr) Composition antipelliculaire permettant de rétablir l'équilibre du cuir chevelu
JP2005015375A (ja) Ａｌｔｅｒｏｍｏｎａｓｍａｃｌｅｏｄｉｉから得られる外分泌性ポリサッカライドを含有することを特徴とする皮膚外用剤
KR20040056079A (ko) 여드름 예방 및 치료용 화장료 조성물
CN106727256A (zh) 一种天然植物复合精油无刺激防晒霜的制备方法
KR101773390B1 (ko) 여드름 개선용 화장료 조성물
KR102874415B1 (ko) 피부 보습, 피부 가려움증 개선 및 피부장벽 강화용 화장료 조성물 및 이를 포함하는 피부 케어 제품

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12786016

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12786016

Country of ref document: EP

Kind code of ref document: A1